A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study.
2022-06-27
عنوان الدراسة
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study.
داعم الدراسة
Novartis
دواء الدراسة
ribociclib
رقم بروتوكول الدراسة
CLEE011A3201C
حالة الدراسة
Terminated
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。